Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi®

NCT07663526 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: TyboWe® Adalimumab Injection

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.